42782-55-8Relevant academic research and scientific papers
Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
-
, (2008/06/13)
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
Structure-activity relationships of alkyl- and alkoxy-substituted 1,4- dihydroquinoxaline-2,3-diones: Potent and systemically active antagonists for the glycine site of the NMDA receptor
Cai, Sui Xiong,Kher, Sunil M.,Zhou, Zhang-Lin,Ilyin, Victor,Espitia, Stephen A.,Tran, Minhtam,Hawkinson, Jon E.,Woodward, Richard M.,Weber, Eckard,Keana, John F. W.
, p. 730 - 738 (2007/10/03)
We report on a series of alkyl- and alkoxy-substituted 1,4- dihydroquinoxaline-2,3-diones (QXs), prepared as a continuation of our structure-activity relationship (SAR) study of QXs as antagonists for the glycine site of the N-methyl-D-aspartate (NMDA) re
